One of the first therapy examples using this approach was the use of a HER2-targeted Affibody molecule,7 which had shown excellent tumor uptake in mice,62 and is in development for metastasized breast cancer.24, 27 The diagnostic agent however, had relatively high kidney uptake levels and could not be directly used for targeting of potent toxic payloads. Here, ERBB2 is linked to neoplasm.